CancerNetwork®

Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.

[CancerNetwork® @CancerNetwrk]

“Every oncologist, every researcher, every IRB has got to know about that study.”

@DrMaurieMarkman, on why LACC tops his ranking of landmark gynecologic oncology trials on Double Blind.

Watch: https://t.co/VfSsrd3zyF

[CancerNetwork® @CancerNetwrk]

The FDA has approved talazoparib plus enzalutamide in metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations.

https://t.co/gS0GRmKqxa

#pcsm #prostatecancer #oncology #cancer | @FDA

[CancerNetwork® @CancerNetwrk]

How can proactive supportive care help patients stay on treatment with subcutaneous amivantamab plus lazertinib?

Wade T. Iams, MD of @TNOncology and @LuisRaezMD discuss COPERNICUS study design, prophylaxis, and brain metastases.

▶️ Watch now: https://t.co/UDhiThPCOq

#NSCLC #EGFR

[CancerNetwork® @CancerNetwrk]

Combining frontline ivonescimab with gemcitabine/cisplatin chemotherapy signficantly prolonged OS vs durvalumab plus chemotherapy among those with advanced biliary tract cancer.

The phase 3 HARMONi-GI1 trial demonstrated that first-line ivonescimab plus chemotherapy may be a new standard of care in this patient population.

https://t.co/sLtvpZ8QjM

#gicsm #ESMO26 | @myESMO

[CancerNetwork® @CancerNetwrk]

Osimertinib plus savolitinib significantly improved PFS and OS vs platinum/pemetrexed chemotherapy in patients with EGFR-mutated, locally advanced or metastatic NSCLC with MET overexpression, MET amplification, or both whose disease had progressed during osimertinib therapy.

Data from the phase 3 SAFFRON trial may support osimertinib plus savolitinib as a new global standard of care in this EGFR-mutated NSCLC population.

https://t.co/sjMqmhdJi5

#lcsm #ESMO26 | @myESMO

[CancerNetwork® @CancerNetwrk]

Divarasib, a next-generation KRAS G12C inhibitor, significantly improved PFS vs sotorasib or adagrasib in advanced or metastatic NSCLC harboring KRAS G12C mutations.

Data from the phase 3 Krascendo 1 trial may support the agent as a new standard in this population.

https://t.co/pvz3MBNu6j

#lcsm | @myESMO

[CancerNetwork® @CancerNetwrk]

That’s a wrap on @DrArturoAI's #ESMO26 takeover! 🎬

AI has moved from demos to data, but the next breakthrough must be clinical. The Presidential Symposium brought 4 phase 3 trials and 4 wins, across melanoma, bladder, small cell lung, and prostate cancer.

The theme of the day: AI reads what we already collect, and drugs get personal. 👋

Thanks for following along and stay tuned for further coverage of the conference!

#OncologyAI #CancerNetwork #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

🕵 @drarturoai was on the ground at #ESMO26 for LBA20.

@LVVPrint presented on the AI Digital MammaPrint, which reads a 70-gene signature from a routine H&E slide, with 95% correlation with the microarray test. In the RASTER cohort, 10-year survival was 98.1% vs 86.7% between low- and high-risk early-stage breast cancer populations.

Regulatory review is pending. 🔬

#OncologyAI #DigitalPathology #bcsm #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

👀 At #ESMO26, @DrArturoAI was in the room for Abstract 170O, presented by Zhen Zhang, PhD.

RADIANT, a radiotherapy foundation model trained on nearly 120,000 cases, contours targets, generates dose plans and predicts outcomes across 4 cancer types, with higher discrimination than standard models.

Clinical utility is still to be proven in model-guided studies. ☢️

#OncologyAI #RadiationOncology #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

OS and PFS improved significantly with tarlatamab plus durvalumab for patients with ES-SCLC.

Data from the phase 3 DeLLphi-305 trial support the regimen as a standard-of-care frontline maintenance option in this patient population.

https://t.co/ZwAiFkMR5C

#SCLC #lcsm | @myESMO @sands_jacob

[CancerNetwork® @CancerNetwrk]

📢 @DrArturoAI was on the floor for LBA19 at #ESMO26!

In ALLIANCE, the first randomized trial of an LLM in the oncologist’s hands, more adverse effects were recorded (5.4 vs 2.8 per patient), but dose reductions and quality of life didn’t change, per Young-Joon Kang, MD, PhD.

Physicians used it in fewer than half of visits, and the tool was safe under physician review.

#OncologyAI #LLMs #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

Belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone produced durable responses and MRD negativity among patients with transplant-ineligible NDMM.

Findings from the phase 1/2 Bela-DRd study support the regimen as an active combination in this setting.

https://t.co/kzSXDKHfQU

#mmsm #ESMO26 | @myESMO @thanosdimop

[CancerNetwork® @CancerNetwrk]

📍 @drarturoai In the room at #ESMO26 for LBA18: @ShazadAshraf88 showed AI that preps the colorectal tumor board before it meets. It earned a 9/10 rating from clinicians and found open trials for 92% of cases, where trials were discussed in fewer than 4% of real cases. Synthetic cases so far; shadow mode is next.

Stay tuned for more coverage!

#crcsm #AIOncology #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma. #melanoma #ESMO26 | @myESMO @ProfGLongMIA

https://t.co/gaT6taYrNz

[CancerNetwork® @CancerNetwrk]

At #ESMO26, @LCUBLD, discussant for the AI and digital health session, spoke with @DrArturoAI and previewed key topics, including AI-driven biomarkers from radiotherapy planning data and H&E slides emulating molecular tests.

Can AI unlock new biomarkers from data we already have?

#OncologyAI #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

🎙️ Live from #ESMO26: @DrArturoAI caught up with Young-Joon Kang, MD, PhD, before the presentation of LBA19, an ALLIANCE randomized trial (NCT07198581).

The trial tested whether a large language model can help clinicians manage chemotherapy adverse effects in patients with breast or colorectal cancer, since symptoms are easy to miss in a busy clinic.

📺 Stay tuned for more from the proffered paper session on AI and digital health!

#bcsm #crcsm #OncologyAI #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor. #ESMO26 #sarcoma | @myESMO

https://t.co/HUmrOiT4Jm

[CancerNetwork® @CancerNetwrk]

🎙️ Reporting in from the Bilbao room at #ESMO26!

@DrArturoAI is settling in for the proffered paper session on AI and digital health, where 3 talks are up next:

🤖 A large language model for detecting adverse events in an Alliance randomized clinical trial

☢️ How AI foundation models are transforming treatment and outcome prediction in radiation oncology

🔬 AI-driven pathology in breast cancer

Stay tuned for takeaways! 👀

#OncologyAI #DigitalHealth #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

Hidden Gem #1 at #ESMO26 ⏰

@DrArturoAI spoke with @massa12d about a melanoma poster, which found that giving immunotherapy earlier in the day was linked to better outcomes, without more immune-related adverse events. The data are retrospective, and randomized trials are underway.

#Melanoma #CNRealtimeReport

[CancerNetwork® @CancerNetwrk]

The EC has approved pembrolizumab plus enfortumab vedotin as neoadjuvant treatment, continued as adjuvant treatment after radical cystectomy, for adults with resectable muscle-invasive bladder cancer.

https://t.co/8snSVOOZsR

#blcsm #bladdercancer #MIBC #oncology #cancer

[CancerNetwork® @CancerNetwrk]

Beyond the big sessions: @DrArturoAI is in Hall 5 at #ESMO26, digging through the exhibit halls and posters for oncology’s hidden gems.

Finds coming soon! 💎

#AI #Oncology #CNRealtimeReport